University of Chicago
The University of Chicago’s Office of Technology & Intellectual Property, (“UChicagoTech“) works with researchers – faculty, students, or staff – to assess the commercial potential of new ideas. UChicagoTech’s goals are to disseminate new ideas so the public can benefit from discoveries, and to generate revenues for research and education.
When the best means of disseminating discoveries and new intellectual property is collaboration between the University and commercial entities, UChicagoTech has a special role to play. We protect the rights of the inventors and the University – and then typically work with industry, granting licenses so that a company will develop the discovery and bring it to the market. Revenues from licenses secured by “UChicagoTech” are shared with the inventor, the inventor’s laboratory, and the inventor’s academic division.
Researchers who have made an advance that might constitute an invention, or who have developed intellectual property – regardless of its commercial potential – should visit our section For Inventors. Or give one of our staff members a call.
If you are a company looking for new ideas to bring to market, please see our section For Industry, or search our Available Technologies. Our staff members can help give you an overview of our policies and guide you to the technologies that best suit your needs.
Innovations (145):
- Phosphatases as a Novel Therapeutic Targets for Adenotonsillar Hypertrophy of Pediatric Sleep Apnea (04 FEB 10)
- Immune Response Regulation for the Treatment of Cancer (17 NOV 09)
- Hybridoma AMS 9.1 (Murine IgD Igh-Ca) (20 OCT 09)
- Hybridoma Producing Monoclonal Antibodies to Mouse IgM (Igh-Cb and related haplotypes) (20 OCT 09)
- a3 domain of mouse H-2Kd MHC class I Monoclonal Antibody Hybridoma (19 OCT 09)
- Inosine-5'-monophosphate Dehydrogenase Monoclonal Antibody Hybridoma (19 OCT 09)
- Real-Time Position Monitoring and Adaptive Head Motion Control Method for Frameless Stereotactic Radiosurgery/Radiotherapy (27 AUG 09)
- Engineered Human APOA-I Proteins for the Treatment of Atherosclerosis (25 AUG 09)
- Monoclonal Antibody Hybridoma to Ovalbumin (18 AUG 09)
- Mouse H2-M3 MHC Class Ib Monoclonal Antibody (18 AUG 09)
Find more innovations
